Astute Medical Gets $6.25M For Biomarker Research

San Diego-based Astute Medical said today that it has raised $6.25M in a Series A funding round. The funding came from De Novo Ventures. According to Astute, the funding will go towards research and development. Astute Medical is focused on developing novel diagnostic tests based an identification and validation of protein biomarkers. The firm was founded by Christopher Hibberd and Paul McPherson, Ph.D., who were formerly at Biosite Incorporated. The firm said its current areas of interest are abdominal pain, acute coronary syndrome, acute kidney injury, congestive heart failure, sepsis, and cerebrovascular disease. More information »